Imanis

Imanis Life Sciences provides research products and contract services for scientists developing cell, gene, and virus therapies. Its offerings include reporter gene lentiviruses, lentiviral vectors, tumor cell lines, targeting reagents, and oncolytic viruses, supporting laboratory studies and noninvasive in vivo imaging. Featured cell lines include 4T1 models engineered with reporters such as eGFP, firefly luciferase, and iRFP, as well as mNIS variants.

The company’s custom services cover cell line development and vector work, including lentiviral and AAV cloning and packaging, lentiviral vector libraries, and vector characterization. Its assay services include cell-based virus neutralization, molecular testing, multiplex cytokine immunoassays, immunophenotyping, vector biodistribution, CAR-T cell characterization, cell proliferation and killing, and vector targeting and specificity. Imanis also conducts contract research in tumor model validation, in vivo efficacy and biodistribution, and platform development. Based in Rochester, Minnesota, the company describes its mission as delivering innovative scientific solutions to challenges in therapeutic development. Its products and services are designed to support research teams with tools, testing, and specialized studies across a range of advanced therapy programs.